Cogstate - Lecanemab Strikes 'home Run' for Alzheimer's Drug Development
The drug reduced clinical cognitive decline by 27% compared to a placebo in a study involving 1,795 participants with early Alzheimer's disease.
357 Views
Cogstate Ltd - Brain Health Is Driving the World and Revenues
Cogstate Ltd Brain health is driving the world and revenues Cogstate (ASX:CGS) works to optimise brain health assessments in clinical...
666 Views
Cogstate - Phase 3 Readouts Underpin the Next Phase of Accelerated Growth
Largely pre-announced, CGS recorded a FY22 group revenue of $45.0m, up +38% pcp, with the clinical trial segment attributing $40.3m, up +41% pcp.
258 Views